🤝 As #ASTRO25 comes to a close, I am reflecting back on it all feeling grateful and inspired. It's always a great time to get together with co-faculty, residents and international GU friends to connect and catch up. The conversations, collaborations, and connections made this

Amazing ⁦#astro⁩25. The best part IMO is connecting with our friends. Safe travels everyone and see you in Boston! ⁦@ASTRO_org⁩ ⁦@MDAndersonNews⁩ ⁦@_ShankarSiva⁩ ⁦@AlexSherryMD⁩ ⁦@ebludmir⁩ ⁦@HimanshuNagarMD⁩ ⁦@VedangMurthy⁩ ⁦

💥Don't miss today's special session at 2:30 PM on radiotherapeutic innovations in #kidneycancer at #ASTRO25! We're proud to partner with @ASTRO_org for this in-depth discussion with an exceptional group of speakers! Link to register 👉 https://t.co/Yek2VEwPsA

Super star in action!

@AlexSherryMD presenting innovative correlative work the hottest basket trial in rad/onc - EXTEND w/ @ChadTangMD

@alison_tree @EmmaHall71 @ICR_London @royalmarsdenNHS GU MCID proportions - when adjusting for mult testing, obstructive domain difference stands out - baseline urinary fcn selection and counseling likely important as well as perhaps borrowing urethra constraints from GU005

The first ever @KidneyCancer and @ASTRO_org symposium happening now! Multidisciplinary discussion across urology, rad onc and med onc focusing on kidney cancer.

Inspired by @PGrivasMDPhD Greek dinner and the ESTRO GU dinner the inaugural IGRT (international GU radiation therapy) dinner kicked off at @ASTRO_org. Thanks for all the amazing GU rad oncs who came out, for my cohost @ndesai2005, and @pfizer / @SumitomoPharma for sponsoring.

Happy to support the efforts of @ebludmir and @AlexSherryMD as the EXTEND pancreas basket publications wins the ROI pub award @ASTRO_org annual meeting. Onwards as we enroll the phase III EXPAND trial led by Ethan. @MDAndersonNews

At #ASTRO25 there are two entire sessions dedicated to #radiotherapy in kidney cancer! #kcsm. All-star🌟 cast, please pop by on Monday and/or Tuesday to learn something interesting about 🫘#radonc! @ASTRO_org @KidneyCancer @PeterMacRadOnc

🔴Online today: Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell #renalcellcarcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial @ChadTangMD https://t.co/WZ8DqrEbiS

@PavlosMsaouel @ebludmir @OncHahn @AlexSherryMD @brian_rini @DrChoueiri @tompowles1 @_ShankarSiva @KidneyCancer @montypal @drdavidpalma @BraunMDPhD @VedangMurthy And of course the utmost respect and thanks for our amazing patients who participated in this study.

@PavlosMsaouel @ebludmir @OncHahn @AlexSherryMD So med oncs, i know we need randomized phase 3 data but hopefully we we can consider this treatment for low volume patients @brian_rini @DrChoueiri @tompowles1 @_ShankarSiva @KidneyCancer @montypal @drdavidpalma @BraunMDPhD @VedangMurthy

Huge shout out to all my coauthors @PavlosMsaouel @ebludmir @OncHahn @AlexSherryMD and many more not on twitter.

We looked at ctDNA using the myriad 2nd generation assay and found 60% of patients to exhibit molecular residual disease. Furthermore this marker was highly prognostic both before and after radiation therapy.

After a median of 3 year follow up. The median systemic therapy free survival was 34 months exceeding our threshold for success. PFS was promising as well with median 17.7 months.

This phase II expansion cohort came on the heals of our original 2021 manuscript demonstrating the feasibility of SBRT alone. We expanded our trial and pre-specified a 2 year systemic therapy survival as our threshold for success.

Excited to share our recent @LancetOncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases. @MDAndersonNews @myriadgenetics https://t.co/UgstAFfvMi

💥Plan to attend an exciting joint session on radiotherapeutic innovations in #kidneycancer at #ASTRO25! There's still time to register! 👉 https://t.co/Yek2VEwPsA We're proud to partner with @ASTRO_org for this special discussion on 9/30!

Don’t miss the @KidneyCancer patient symposium on Sept 6! Our virtual tumor board will dive into treatment decision-making in kidney cancer. I really enjoyed participating and learning from the experts. @UWCarbone @wiscurology